文献速递肥胖与代谢综合征糖尿病

美国青少年代谢功能障碍相关脂肪性肝病及心血管代谢危险因素的患病率

Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease and Cardiometabolic Risk Factor in US Adolescents.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本研究为横断面研究,纳入2017至2020周期美国国家健康与营养调查中12至19岁青少年,评估代谢功能障碍相关脂肪性肝病(MASLD)患病率及其与心血管代谢危险因素(CMRFs)的关系。青少年MASLD患病率为23.77%,超重/肥胖是最主要的CMRF,超重/肥胖与血脂异常或血糖升高对肝脂肪变存在正向相加交互作用。

要点

  • 美国青少年MASLD患病率为23.77%。
  • 超重/肥胖是最主要的CMRF,单独超重/肥胖占35%。
  • 超重/肥胖与血脂异常或血糖升高对肝脂肪变有正向相加交互作用。

核心结论

  • 青少年MASLD患病率极高,超重/肥胖是最重要的CMRF。
  • 超重/肥胖与血脂异常或血糖升高对肝脂肪变存在正向相加交互效应。

研究设计与样本

  • 横断面研究,纳入2017至2020周期美国国家健康与营养调查中12至19岁美国青少年。
  • 通过中位受控衰减参数(CAP)评估肝脂肪变,分析CMRFs与肝脂肪变的关系。

主要发现

  • 青少年MASLD患病率为23.77%。
  • 单独超重/肥胖是最主要的CMRF,占35%。
  • 非西班牙裔黑人超重/肥胖加血糖升高比例最高,为24%;非西班牙裔亚洲人血脂异常负担最高,分别为2%、14%和19%。
  • 除高血压外,超重/肥胖(β=48.7;95%CI,43.4-54.0)、高甘油三酯血症(β=15.5;95%CI,7.2-28.3)、低HDL-C(β=10.0;95%CI,3.1-16.9)、血糖升高(β=6.9;95%CI,0.6-13.2)均与CAP值升高显著相关。
  • 超重/肥胖与血糖升高交互作用:RERI=8.21,AP=0.45,SI=1.91;超重/肥胖与高甘油三酯血症:RERI=19.00,AP=0.69,SI=3.53;超重/肥胖与低HDL-C:RERI=10.83,AP=0.58,SI=2.61。

关键数值与推荐

  • 超重/肥胖合并血脂异常者β=15.1(95%CI,0.1-30.2);超重/肥胖、血脂异常和血糖升高三者合并者β=48.0(95%CI,23.3-72.6),CAP值显著更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is widespread worldwide, and a strong link between MASLD and cardiometabolic risk factors (CMRFs) was highlighted in this study. OBJECTIVE: This study characterized the prevalence of MASLD in adolescent population and overlapping CMRFs conditions in MASLD. METHODS: This is a cross-sectional study of US adolescents aged 12 to 19 years in the 2017 through 2020 cycles of the National Health and Nutrition Examination Survey. The relationship between CMRFs and liver steatosis, evaluated by the median controlled attenuation parameter (CAP), was assessed. RESULTS: The prevalence of MASLD in adolescents was 23.77%. Isolated overweight/obesity (35%) was the top CMRF. Non-Hispanic Black patients had the highest proportion of overweight/obesity plus elevated glucose (24%), whereas non-Hispanic Asians had the highest burden of dyslipidemia (2%, 14%, and 19%). Except for hypertension, overweight/obesity (β = 48.7; 95% CI, 43.4-54.0), hypertriglyceridemia (β = 15.5; 95% CI, 7.2-28.3), low HDL-C (β = 10.0; 95% CI, 3.1-16.9), elevated glucose (β = 6.9; 95% CI, 0.6-13.2) were all significantly associated with increased CAP values. Increased CAP was linked to the synergistic interactions between overweight/obesity and dyslipidemia or elevated glucose (overweight/obesity and elevated glucose: relative excess risk due to interaction [RERI] = 8.21, attributable proportion due to interaction [AP] = 0.45, synergy index [SI] = 1.91; overweight/obesity and hypertriglyceridemia: RERI = 19.00, AP = 0.69, SI = 3.53; overweight/obesity and low high-density lipoprotein cholesterol: RERI = 10.83, AP = 0.58, SI = 2.61). Adolescents with combination of overweight/obesity, dyslipidemia (β = 15.1; 95% CI, 0.1-30.2) and combination of overweight/obesity, dyslipidemia and elevated glucose (β = 48.0; 95% CI, 23.3-72.6) had a significantly higher CAP values. CONCLUSION: The prevalence of MASLD was alarmingly high in adolescents, and overweight/obesity was the most important CMRF. Overweight/obesity and dyslipidemia or elevated glucose had positive additive interaction effects on liver steatosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zheng X, Zhao D, Wang L, et al. Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease and Cardiometabolic Risk Factor in US Adolescents. J Clin Endocrinol Metab. 2025. PMID: 39136243. doi:10.1210/clinem/dgae553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。